Horizon 2020 Dedicated SME instrument - Health
The Horizon 2020 Dedicated SME Instrument directly supports European small and medium-sized enterprises with a strong desire to develop, grow, and internationalize their most innovative ideas.
The instrument is relevant for high-tech and research driven companies as well as service companies, and SMEs applying in a consortium or alone. With a successful application to the program, companies will receive:
-
Phase 1: A lump sum of EUR 50,000 towards proof-of-concept and feasibility studies
-
Phase 2: EUR 0.5-2.5M towards innovation development and demonstration activities
-
Support of up to 70% of total project cost
Below are the upcoming deadlines for Horizon 2020 SME Instrument. Expect 1-2 months for the proposal writing process.
SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector (Phase 2)
Deadline: April 06, 2017
The healthcare biotechnology sector offers huge business and commercial opportunities; however it also requires heavy and risky investments which are often lacking in Europe, hampering the development of the industry.
Cell technologies in medical applications
Cell technologies include cell manufacturing (culture, multiplication, scale-up and automation), preservation, banking and transport; identification, cell sorting and delivery, imaging, tracking, process and quality control; genetic engineering and gene editing; production of therapeutic biomolecules.
SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector (Phase 2)
Deadline: April 06, 2017
The healthcare biotechnology sector offers huge business and commercial opportunities; however it also requires heavy and risky investments which are often lacking in Europe, hampering the development of the industry.
Clinical research for the validation of biomarkers and/or diagnostic medical devices.
Biomarkers are used in clinical practice to indicate both normal and pathological conditions. They are also used for predictive or prognostic purposes. They are being used increasingly in medicine and many potential new biomarkers are proposed every year. However, only a few of these have been validated for clinical use. To achieve validation a robust analytical method is required and a link to a pertinent clinical process or endpoint needs to be demonstrated.
SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector (Phase 2)
Deadline: June 01, 2017
The healthcare biotechnology sector offers huge business and commercial opportunities; however it also requires heavy and risky investments which are often lacking in Europe, hampering the development of the industry.
Cell technologies in medical applications
Cell technologies include cell manufacturing (culture, multiplication, scale-up and automation), preservation, banking and transport; identification, cell sorting and delivery, imaging, tracking, process and quality control; genetic engineering and gene editing; production of therapeutic biomolecules.
SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector (Phase 2)
Deadline: June 01, 2017
The healthcare biotechnology sector offers huge business and commercial opportunities; however it also requires heavy and risky investments which are often lacking in Europe, hampering the development of the industry.
Clinical research for the validation of biomarkers and/or diagnostic medical devices.
Biomarkers are used in clinical practice to indicate both normal and pathological conditions. They are also used for predictive or prognostic purposes. They are being used increasingly in medicine and many potential new biomarkers are proposed every year. However, only a few of these have been validated for clinical use. To achieve validation a robust analytical method is required and a link to a pertinent clinical process or endpoint needs to be demonstrated.
SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector (Phase 2)
Deadline: October 18, 2017
The healthcare biotechnology sector offers huge business and commercial opportunities; however it also requires heavy and risky investments which are often lacking in Europe, hampering the development of the industry.
Cell technologies in medical applications
Cell technologies include cell manufacturing (culture, multiplication, scale-up and automation), preservation, banking and transport; identification, cell sorting and delivery, imaging, tracking, process and quality control; genetic engineering and gene editing; production of therapeutic biomolecules.
SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector (Phase 2)
Deadline: October 18, 2017
The healthcare biotechnology sector offers huge business and commercial opportunities; however it also requires heavy and risky investments which are often lacking in Europe, hampering the development of the industry.
Clinical research for the validation of biomarkers and/or diagnostic medical devices.
Biomarkers are used in clinical practice to indicate both normal and pathological conditions. They are also used for predictive or prognostic purposes. They are being used increasingly in medicine and many potential new biomarkers are proposed every year. However, only a few of these have been validated for clinical use. To achieve validation a robust analytical method is required and a link to a pertinent clinical process or endpoint needs to be demonstrated.
Ependysis Business Consultants can prepare you in the submission of the investment file, as well as help you arrange the partners of the project.